Follistatin vs Dulaglutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Follistatin
Follistatin is a glycoprotein that inhibits myostatin, the protein responsible for limiting muscle growth. By blocking myostatin, follistatin can theoretically allow for increased muscle development beyond natural limits.
Full details →Dulaglutide
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Full details →Side-by-Side Comparison
| Aspect | Follistatin | Dulaglutide |
|---|---|---|
| Mechanism | Binds to and neutralizes myostatin and activin, both of which are negative regulators of muscle mass. This removes the natural brake on muscle growth, allowing for enhanced hypertrophy. | GLP-1 analog fused to a modified human IgG4 Fc fragment, providing extended duration of action. Activates GLP-1 receptors for glucose-dependent insulin secretion and appetite suppression. |
| Typical Dosage | Research protocols typically use 100-300mcg daily, though optimal dosing is not well established. Gene therapy approaches have also been studied. | Start at 0.75mg once weekly, may increase to 1.5mg, 3mg, or maximum 4.5mg weekly based on glycemic response. |
| Administration | Subcutaneous injection. Different isoforms exist (FS344, FS315) with varying properties. Requires careful sourcing due to complexity. | Subcutaneous injection once weekly, any time of day, with or without food. Comes in pre-filled single-dose pens. |
| Side Effects | Limited human data. Theoretical concerns about effects on other organs where activin signaling is important. | Nausea, diarrhea, vomiting, abdominal pain, decreased appetite. Generally well-tolerated with gradual dose titration. |
| Best For |